Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus CENTANY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus CENTANY.
BACI-RX vs CENTANY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic